about
Targeted disruption of Ing2 results in defective spermatogenesis and development of soft-tissue sarcomasProteomic analysis of formalin-fixed prostate cancer tissue.Quantitative expression profile of PSGR in prostate cancer.Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival.Quantitative analysis of a panel of gene expression in prostate cancer--with emphasis on NPY expression analysis.Delineation of TMPRSS2-ERG splice variants in prostate cancer.Osteoblast-specific factor 2 expression in prostate cancer-associated stroma: identification through microarray technology.Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion status.Evaluation of ERG responsive proteome in prostate cancerLoss of PTEN is associated with aggressive behavior in ERG-positive prostate cancerAssessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors.PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.Sarcoidosis of the prostate.CXCR4 and cancer.Orbital solitary fibrous tumor: encompassing terminology for hemangiopericytoma, giant cell angiofibroma, and fibrous histiocytoma of the orbit: reappraisal of 41 cases.Novel human prostate epithelial cell culture models for the study of carcinogenesis and of normal stem cells and cancer stem cells.Increased aPKC Expression Correlates with Prostatic Adenocarcinoma Gleason Score and Tumor Stage in the Japanese Population.Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer.Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.Telomerase-immortalized non-malignant human prostate epithelial cells retain the properties of multipotent stem cells.ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratificationPhenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines.Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients.The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma.Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy.Differences in prostate cancer grade, stage, and location in radical prostatectomy specimens from United States and Japan.Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice.TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.Allelotyping analysis at chromosome arm 8p of high-grade prostatic intraepithelial neoplasia and incidental, latent, and clinical prostate cancers.Ultrasound-accelerated formalin fixation of tissue improves morphology, antigen and mRNA preservation.Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimensDo patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy?Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progressionClinicopathological behavior of single focus prostate adenocarcinoma
P50
Q24310863-B0964859-7DBA-4611-B959-C282F735E593Q33221442-5D5E7137-9237-4B16-AB94-4E5C08052C7AQ33225361-5AC0A933-9B60-4266-970D-943BB7E746CFQ33312298-D704D2EE-BAFF-4206-B7AF-E66669D06909Q33317938-F1DE2FE2-1B2D-4863-AA1C-578FA5DA743DQ33318669-85701F18-7100-4C05-8006-E16462F05BB5Q33357287-FD37E04B-178E-4FE2-BB33-A8BAFCE9FADBQ33520853-6364AA2A-A0A4-4935-A341-CF212BB011E1Q33645816-0A0ABC02-933C-4B64-98A0-0B2AC2851ADFQ33822319-3608BB42-2884-4737-8528-D704EB8BA21BQ33862890-BB1FD541-DD39-4BB7-9567-4DC86DDDA254Q34138364-426717A7-B5D9-4A7A-9D57-80536BF09BCFQ34830787-05EA305B-67BC-4F8F-9FFE-2DFA785C58AAQ36755170-13EE0C05-59F2-4082-8F1E-8320679F5188Q37769282-8C25ADA2-9F4C-4783-A0FF-EF0581307FCEQ37807822-F3FE5657-1E58-4A76-BEE0-0F95BDD11F42Q37929039-3675C977-F720-49CF-8A8C-6F8A2D367181Q39585024-C9BE7C6D-3B55-465D-BE8C-02ED773415BEQ39919769-D48F85C9-893B-4ECF-8C8D-8063294E8AE4Q40038137-84FAB81C-9608-4E46-83E1-C1CD9BE1CAB3Q40075274-65C964BE-9651-4E3B-B68A-67F274F251D7Q41489983-DE3E4A79-7F8D-4833-B7F5-29A02E19CA2EQ42167180-7338BC59-EC63-44B4-A49B-BEDEC9E63E45Q43962349-7D321298-F12B-4170-849E-0785007F4454Q45754459-464DAD0A-50C5-4BA4-88C1-BD882F8C634DQ46232748-F7F7B063-F3F0-4932-9C2B-339DAF6D94BCQ46687880-1A6C47B3-BFD3-446C-AE70-D278324A0EB5Q54377548-1DECDD7F-1412-41DE-A8FD-C883E49E4076Q54529505-1BFAB2CA-BB2E-4A62-B424-979A4E01A1D3Q54618429-07E4CAA5-0F21-4FB2-A0EF-F71E488BCEF6Q54688883-434B6EA6-F6E2-45D6-BBDB-24243FDC84E8Q80099843-34315D5F-9A08-46B4-8671-AEEB493919F9Q81451592-E55C59AC-E783-47B0-A3E4-9EDD17C78086Q83463350-8BA872C6-7C21-405F-8438-3EFC27663746Q84739739-41E45E30-EA3C-4ABE-9EE9-BD9EFA071912
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Bungo Furusato
@ast
Bungo Furusato
@en
Bungo Furusato
@es
Bungo Furusato
@nl
Bungo Furusato
@sl
type
label
Bungo Furusato
@ast
Bungo Furusato
@en
Bungo Furusato
@es
Bungo Furusato
@nl
Bungo Furusato
@sl
altLabel
Bungo Furusato
@en
prefLabel
Bungo Furusato
@ast
Bungo Furusato
@en
Bungo Furusato
@es
Bungo Furusato
@nl
Bungo Furusato
@sl
P106
P1153
12779343300
P31
P496
0000-0003-4614-9882